Specific and high-affinity binding of tetramerized PD-L1 extracellular domain to PD-1-expressing cells: possible application to enhance T cell function.
暂无分享,去创建一个
Yoshimasa Tanaka | B. Mikami | T. Okazaki | T. Honjo | N. Minato | D. Garboczi | Tamon Hayashi | Shiro Shibayama | S. Terawaki | T. Nagakura | Kaori Muroi | Taku Okazaki
[1] R. Koup,et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection , 2006, The Journal of experimental medicine.
[2] Philip J. R. Goulder,et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression , 2006, Nature.
[3] R. Balderas,et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction , 2006, Nature Medicine.
[4] G. Freeman,et al. Restoring function in exhausted CD8 T cells during chronic viral infection , 2006, Nature.
[5] T. Okazaki,et al. Hydronephrosis associated with antiurothelial and antinuclear autoantibodies in BALB/c-Fcgr2b −/− Pdcd1 −/− mice , 2005, The Journal of experimental medicine.
[6] P. Saunders,et al. PD‐L2:PD‐1 involvement in T cell proliferation, cytokine production, and integrin‐mediated adhesion , 2005, European journal of immunology.
[7] T. Okazaki,et al. Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[8] M. Azuma,et al. Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer , 2005, Clinical Cancer Research.
[9] D. Stuart,et al. Crystal structure of a soluble CD28-Fab complex , 2005, Nature Immunology.
[10] G. Zhu,et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. , 2005, Cancer research.
[11] T. Honjo,et al. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. , 2004, International immunology.
[12] M. Nishimura,et al. B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression , 2004, Clinical Cancer Research.
[13] C. June,et al. SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1 , 2004, The Journal of Immunology.
[14] S. Almo,et al. Erratum: Structural and functional analysis of the costimulatory receptor programmed death-1 (Immunity (March 2004) 20 (337-347)) , 2004 .
[15] Michael Cammer,et al. Structural and functional analysis of the costimulatory receptor programmed death-1. , 2004, Immunity.
[16] Yoshimasa Tanaka,et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice , 2003, Nature Medicine.
[17] G. Freeman,et al. Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses , 2003, European journal of immunology.
[18] J. Cheville,et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. , 2003, Cancer research.
[19] S. Khoury,et al. Critical Role of the Programmed Death-1 (PD-1) Pathway in Regulation of Experimental Autoimmune Encephalomyelitis , 2003, The Journal of experimental medicine.
[20] S. Khoury,et al. The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice , 2003, The Journal of experimental medicine.
[21] T. Okazaki,et al. PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver , 2003, The Journal of experimental medicine.
[22] T. Curiel,et al. Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.
[23] G. Freeman,et al. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. , 2002, Immunology letters.
[24] Yoshimasa Tanaka,et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[25] Haidong Dong,et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.
[26] H. Schneider,et al. A regulatory role for cytoplasmic YVKM motif in CTLA‐4 inhibition of TCR signaling , 2001, European journal of immunology.
[27] T. Honjo,et al. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. , 2001, Trends in immunology.
[28] D. Pardoll,et al. B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells , 2001, The Journal of experimental medicine.
[29] C. Chambers. The expanding world of co-stimulation: the two-signal model revisited. , 2001, Trends in immunology.
[30] G. Freeman,et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.
[31] T. Okazaki,et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. , 2001, Science.
[32] G. Freeman,et al. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.
[33] S. Dzik. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin 10 secretion , 2000 .
[34] T. Honjo,et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. , 1999, Immunity.
[35] P. Schwartzberg,et al. Resting lymphocyte kinase (Rlk/Txk) phosphorylates the YVKM motif and regulates PI 3-kinase binding to T-cell antigen CTLA-4. , 1998, Biochemical and biophysical research communications.
[36] Philip J. R. Goulder,et al. Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.
[37] D. Olive,et al. Binding of phosphatidyl-inositol-3-OH kinase to CD28 is required for T-cell signalling , 1994, Nature.
[38] A. Weiss,et al. The cytoplasmic domain of CD28 is both necessary and sufficient for costimulation of interleukin-2 secretion and association with phosphatidylinositol 3'-kinase , 1994, Molecular and cellular biology.
[39] L. Cantley,et al. T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[40] P. Schatz. Use of Peptide Libraries to Map the Substrate Specificity of a Peptide-Modifying Enzyme: A 13 Residue Consensus Peptide Specifies Biotinylation in Escherichia coli , 1993, Bio/Technology.
[41] C. Nelson,et al. Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice , 1988, Nature.
[42] R. Lloubès,et al. Translation is a non-uniform process. Effect of tRNA availability on the rate of elongation of nascent polypeptide chains. , 1984, Journal of molecular biology.
[43] G. Freeman,et al. The B7 family revisited. , 2005, Annual review of immunology.
[44] 岡崎 拓. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine , 2003 .
[45] S. Almo,et al. Structural mechanisms of costimulation , 2002, Nature Immunology.
[46] D. Olive,et al. Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling , 1994, Nature.
[47] G D Stormo,et al. High-level translation initiation. , 1990, Methods in enzymology.